Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07088926 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization
A Phase 2 study of Bronchiectasis With Pseudomonas Aeruginosa Colonization, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 435
- Enrollment target
- 20
- Study locations
NCT07088926: Recruiting Phase 2 study of Bronchiectasis With Pseudomonas Aeruginosa Colonization, sponsored by AstraZeneca.
NCT07088926 is a Phase 2 study of Bronchiectasis With Pseudomonas Aeruginosa Colonization that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 435 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (227% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07088926, a Phase 2 study of Bronchiectasis With Pseudomonas Aeruginosa Colonization, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 435 participants
- Enrollment target
- 20
- Study locations
Study Summary
AZD0292 is a bispecific IgG1k mAb being evaluated for the prevention of exacerbations in bronchiectasis patients chronically colonized with PsA.
Primary Outcome
To evaluate the effect of IV AZD0292 compared to placebo on the rate of moderate-to-severe pulmonary exacerbations in participants with NCFBE and chronic colonization with PsA.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL AZD0292
Study Locations (20)
Florida
- Research Site - Jacksonville
- Research Site - Miami Lakes
- Research Site - Naples
- Research Site - Ormond Beach
- Research Site - Plantation
California
- Research Site - Orange
- Research Site - San Francisco
Pennsylvania
- Research Site - DuBois
- Research Site - Philadelphia
Colorado
- Research Site - Denver
District of Columbia
- Research Site - Washington D.C.
Georgia
- Research Site - Rincon
Kansas
- Research Site - Kansas City
Michigan
- Research Site - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 435 participants |
| Start Date | 2025-11-06 |
| Est. Completion | 2028-06-14 |
| Phase | Phase 2 |
What NCT07088926 shows while recruiting
NCT07088926 is an interventional study that assigns participants to a tested intervention. The registered 435 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (227% higher).
The record links to 1 condition, with Bronchiectasis With Pseudomonas Aeruginosa Colonization appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07088926 names 20 study sites across 14 states, led by Florida, California, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT07088926 about?
NCT07088926 is a clinical study titled "A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization". AZD0292 is a bispecific IgG1k mAb being evaluated for the prevention of exacerbations in bronchiectasis patients chronically colonized with PsA.
What is the current status of trial NCT07088926?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 435 participants. The study started on 2025-11-06. Estimated completion is 2028-06-14.
What conditions does trial NCT07088926 study?
This clinical trial studies the following conditions: Bronchiectasis With Pseudomonas Aeruginosa Colonization.
What interventions are being tested in trial NCT07088926?
The interventions under investigation include: Placebo (OTHER), AZD0292 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07088926?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07088926 being conducted?
This trial has 20 study locations across California, Colorado, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07088926's enrollment target sits among peer trials
435 90th of 2000 higher than 1,911 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05563220 · 435 participants · Phase 1
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer
- NCT02622542 · 436 participants · NA
ACute Uncomplicated Type b Aortic Dissection: Endovascular Repair vs. Best Medical Therapy
- NCT05918211 · 436 participants · Phase 3
Fontan Udenafil Exercise Longitudinal Assessment Trial - 2
- NCT06966479 · 436 participants · Phase 2
A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI